Advertisement

Meta-analysis of efficacy and safety of continuous saline bladder irrigation compared with intravesical chemotherapy after transurethral resection of bladder tumors

  • Zhongbao Zhou
  • Shikai Zhao
  • Youyi Lu
  • Jitao Wu
  • Yongwei Li
  • Zhenli Gao
  • Diandong YangEmail author
  • Yuanshan CuiEmail author
Review
  • 47 Downloads

Abstract

Purpose

We performed a meta-analysis to confirm the efficacy and safety of continuous saline bladder irrigation compared with intravesical chemotherapy after transurethral resection for the treatment of non-muscle invasive bladder cancer.

Methods

Randomized controlled trials of continuous saline bladder irrigation compared with intravesical chemotherapy were searched using MEDLINE, EMBASE, and the Cochrane Controlled Trials Register. The data were evaluated and statistically analyzed using RevMan version 5.3.0.

Results

Four studies including 861 participants which compared continuous saline bladder irrigation with intravesical chemotherapy were considered. One-year recurrence-free survival [odds ratio (OR) = 0.76, 95% CI = 0.55–1.05, p = 0.09]; 2-year recurrence-free survival (OR = 0.94, 95% CI = 0.71–1.25, p = 0.68); the median period to first recurrence (OR = − 1.01, 95% CI = − 2.96 to 0.94, p = 0.31); the number of tumor progression (OR = 0.80, 95% CI = 0.54–1.17, p = 0.25); and the number of recurrence during follow-up (OR = 1.12, 95% CI = 0.84–1.50, p = 0.43) suggested that two methods of postoperative perfusion had no significant differences. In terms of safety, including macrohematuria, frequency of urination and bladder irritation symptoms, continuous saline bladder irrigation showed better tolerance than intravesical chemotherapy.

Conclusion

Continuous saline bladder irrigation seems to provide a better balance between prevention of recurrence and local toxicities than intravesical chemotherapy after transurethral resection of bladder tumors.

Keywords

Non-muscle invasive bladder cancer Meta-analysis Randomized controlled trials Continuous saline bladder irrigation Transurethral resection of bladder tumors 

Notes

Author contributions

DY and YC participated in the design of this study. JW performed the statistical analysis. YL and YL collected important background information. ZZ and SZ drafted the manuscript. ZG conceived this study, participated in the design and helped to draft the manuscript. All authors read and approved the final manuscript.

Funding sources

Unfunded.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethics approval and consent to participate

The authors have no ethical conflicts to disclose.

References

  1. 1.
    Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68:7–30CrossRefGoogle Scholar
  2. 2.
    Kamat AM, Hegarty PK, Gee JR, Clark PE, Svatek RS, Hegarty N et al (2013) ICUD-EAU International Consultation on Bladder Cancer 2012: screening, diagnosis, and molecular markers. Eur Urol 63(1):4–15CrossRefGoogle Scholar
  3. 3.
    Mishriki SF, Nabi G, Cohen NP (2008) Diagnosis of urologic malignancies in patients with asymptomatic dipstick hematuria: prospective study with 13 years’ follow-up. Urology 71(1):13–16CrossRefGoogle Scholar
  4. 4.
    Richards KA, Smith ND, Steinberg GD (2014) The importance of transurethral resection of bladder tumor in the management of nonmuscle invasive bladder cancer: a systematic review of novel technologies. J Urol 191(6):1655–1664CrossRefGoogle Scholar
  5. 5.
    Brausi M, Witjes JA, Lamm D, Persad R, Palou J, Colombel M, Buckley R, Soloway M, Akaza H, Bohle A (2011) A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J Urol 186(6):2158–2167CrossRefGoogle Scholar
  6. 6.
    Oddens JR, van der Meijden AP, Sylvester R (2004) One immediate postoperative instillation of chemotherapy in low risk Ta, T1 bladder cancer patients. Is it always safe? Eur Urol 46(3):336–338CrossRefGoogle Scholar
  7. 7.
    Onishi T, Sugino Y, Shibahara T, Masui S, Yabana T, Sasaki T (2017) Randomized controlled study of the efficacy and safety of continuous saline bladder irrigation after transurethral resection for the treatment of non-muscle-invasive bladder cancer. BJU Int 119(2):276–282CrossRefGoogle Scholar
  8. 8.
    Nojiri Y, Okamura K, Kinukawa T, Ozawa H, Saito S, Okumura K, Terai A, Takei M (2007) Continuous bladder irrigation following transurethral resection of the prostate (TURP). Nihon Hinyokika Gakkai Zasshi 98(6):770–775Google Scholar
  9. 9.
    Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151:264–269CrossRefGoogle Scholar
  10. 10.
    Jadad AR (1998) Randomised controlled trials. BMJ Publishing Group, LondonGoogle Scholar
  11. 11.
    Higgins JP, Green S (2011) Cochrane handbook for systematic reviews of interventions. Version 5.1.0. The Cochrane collaboration. Updated Mar 2011. http://www.cochrane-handbook.org. Cited 10 May 2017
  12. 12.
    DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177–188CrossRefGoogle Scholar
  13. 13.
    Maekawa S, Suzuki H, Ohkubo K, Aoki Y, Okada T, Maeda H, Ogura K, Arai Y (2000) Continuous intravesical instillation of epirubicin immediately after transurethral resection of superficial bladder cancer: a prospective controlled study. Hinyokika kiyo Acta Urologica Japonica 46(5):301–306Google Scholar
  14. 14.
    Bohle A, Leyh H, Frei C, Kuhn M, Tschada R, Pottek T, Wagner W, Knispel HH, von Pokrzywnitzki W, Zorlu F, Helsberg K, Lubben B, Soldatenkova V, Stoffregen C, Buttner H (2009) Single postoperative instillation of gemcitabine in patients with non-muscle-invasive transitional cell carcinoma of the bladder: a randomised, double-blind, placebo-controlled phase III multicentre study. Eur Urol 56(3):495–503CrossRefGoogle Scholar
  15. 15.
    Onishi T, Sasaki T, Hoshina A, Yabana T (2011) Continuous saline bladder irrigation after transurethral resection is a prophylactic treatment choice for non-muscle invasive bladder tumor. Anticancer Res 31(4):1471–1474Google Scholar
  16. 16.
    Amling CL (2001) Diagnosis and management of superficial bladder cancer. Curr Probl Cancer 25(4):219–278CrossRefGoogle Scholar
  17. 17.
    Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49(3):466–477CrossRefGoogle Scholar
  18. 18.
    Furuse H, Ozono S (2010) Transurethral resection of the bladder tumour (TURBT) for non-muscle invasive bladder cancer: basic skills. Int J Urol 17(8):698–699CrossRefGoogle Scholar
  19. 19.
    Divrik RT, Yildirim U, Zorlu F, Ozen H (2006) The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. J Urol 175(5):1641–1644CrossRefGoogle Scholar
  20. 20.
    Sylvester RJ, Oosterlinck W, van der Meijden A (2004) A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 171:2186–2190CrossRefGoogle Scholar
  21. 21.
    Gudjonsson S, Adell L, Merdasa F, Olsson R, Larsson B, Davidsson T, Richthoff J, Hagberg G, Grabe M, Bendahl PO, Mansson W, Liedberg F (2009) Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study. Eur Urol 55(4):773–780CrossRefGoogle Scholar
  22. 22.
    Do J, Lee SW, Jeh SU, Hwa JS, Hyun JS, Choi SM (2018) Overnight continuous saline irrigation after transurethral resection for non-muscle-invasive bladder cancer is helpful in prevention of early recurrence. Can Urol Assoc J 12(11):E480–E483CrossRefGoogle Scholar
  23. 23.
    Seo HK, Ahn KO, Jung NR et al (2017) Solubilization and stability of mitomycin C solutions prepared for intravesical administration. Drugs R&D 17(2):297–304CrossRefGoogle Scholar
  24. 24.
    Oosterlinck W, Kirkali Z, Sylvester R, da Silva FC, Busch C, Algaba F, Collette S, Bono A (2011) Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guerin and with bacillus Calmette-Guerin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 trial (30993). Eur Urol 59:438–446CrossRefGoogle Scholar
  25. 25.
    Chen L, Pan XW, Huang H, Gao Y, Yang QW, Wang LH, Cui XG, Xu DF (2017) Epithelial-mesenchymal transition induced by GRO-alpha-CXCR2 promotes bladder cancer recurrence after intravesical chemotherapy. Oncotarget 8(28):45274–45285Google Scholar
  26. 26.
    Soloway SM, Masters S (1980) Urothelial susceptibility to tumor cell implantation: influence of cauterization. Cancer 46:1158–1163CrossRefGoogle Scholar
  27. 27.
    Lenis AT, Asanad K, Blaibel M, Donin NM, Chamie K (2018) Continuous saline bladder irrigation for two hours following transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer does not prevent recurrence or progression compared with intravesical Mitomycin-C. BMC Urol 18(1):93CrossRefGoogle Scholar
  28. 28.
    Nieuwenhuijzen JA, Bex A, Horenblas S (2003) Unusual complication after early Mitomycin C instillation. Eur Urol 43:711–712CrossRefGoogle Scholar
  29. 29.
    Elmamoun MH, Christmas TJ, Woodhouse CR (2014) Destruction of the bladder by single dose Mitomycin C for low-stage transitional cell carcinoma (TCC)—avoidance, recognition, management and consent. BJU Int 113:E34–E38CrossRefGoogle Scholar
  30. 30.
    Stenzl A, Jocham D, Jichlinski P, Junker K, König F et al (2008) Photodynamic diagnostics in the urinary tract Consensus paper of the Working Group for Oncology of the German Society for Urology. Urologe A 47:982–987CrossRefGoogle Scholar
  31. 31.
    Lee CS, Yoon CY, Witjes JA (2008) The past, present and future of cystoscopy: the fusion of cystoscopy and novel imaging technology. BJU Int 102(9 Pt B):1228–1233CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Zhongbao Zhou
    • 1
    • 2
  • Shikai Zhao
    • 3
  • Youyi Lu
    • 2
  • Jitao Wu
    • 2
  • Yongwei Li
    • 2
  • Zhenli Gao
    • 2
  • Diandong Yang
    • 2
    Email author
  • Yuanshan Cui
    • 2
    Email author
  1. 1.Binzhou Medical UniversityYantaiChina
  2. 2.Department of UrologyThe Affiliated Yantai Yuhuangding Hospital of Qingdao UniversityYantaiChina
  3. 3.Department of AndrologyThe Liaocheng People’s HospitalLiaochengChina

Personalised recommendations